Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

Acta Neurologica Scandinavica - 2025 - Muñoz-Vendrell - Monthly Versus Quarterly Fremanezumab in Real Life A Comparison of.pdf (938.97 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-01-01

Llicència de publicació

cc-by (c) Muñoz Vendrell, Albert et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222960

Monthly versus quarterly Fremanezumab in real life: a comparison of effectiveness, tolerability, and adherence

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1155/ane/6650009

Resum

Background: While clinical trials have shown no differences between monthly and quarterly regimens of fremanezumab, limited real-life data exist for comparison. This study is aimed at comparing treatment regimens in real life.Methods: This observational, multicentre study conducted a retrospective analysis of patients initiating monthly or quarterly fremanezumab. Primary endpoints were the comparison of monthly migraine days' reduction, adverse effects, and treatment discontinuation rates at 3 and 6 months. Secondary endpoints included changes in headache and medication intake frequencies, response rates, and patient-reported outcomes.Results: One hundred and eleven patients were included, with a median age of 48.5 years, 91% women, and 54.1% with chronic migraine. Sixty-four patients received a monthly regimen and 47 a quarterly. Baseline characteristics were similar. Reductions in monthly migraine days did not differ between treatment regimens (-5 [IQR -9, -1] for monthly versus -6 [IQR -8, -3] for quarterly at 3 months, p = 0.867, and -5 [IQR -10, -2] versus -5.5 [IQR -8.5, -3] at 6 months, p = 0.666, respectively). Adverse effects and discontinuation rates were similar between groups. Secondary endpoints were comparable, except for a higher PGIC scale for the quarterly group at 6 months (6 [IQR 4-6] versus 4 [IQR 2-6], p = 0.007). No differences were observed in the subgroup analysis of episodic or chronic migraine.Conclusions: Monthly and quarterly fremanezumab demonstrated comparable effectiveness, tolerability, and adherence in real life. Quarterly regimen may result in a more favorable global impression of change.

Matèries

Migranya, Assaigs clínics, Terapèutica

Matèries (anglès)

Migraine, Clinical trials, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MUÑOZ VENDRELL, Albert, et al. Monthly versus quarterly Fremanezumab in real life: a comparison of effectiveness, tolerability, and adherence. Acta Neurologica Scandinavica. 2025. Vol. 2025, num. 1. ISSN 1600-0404. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/222960

Exportar metadades

JSON - METS

Compartir registre